Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,130 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00280202 | Detection of Genetic Markers of Lung Cancer | recruiting | — | 6,000 | University of PittsburghOTHER | 1 | Oct 24, 2025 | clinicaltrials |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1) | recruiting | Phase 1 / Phase 2 | 250 | Krystal Biotech, Inc.INDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT01720836 | Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 30 | Olivera FinnOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT04991025 | Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery | recruiting | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05292521 | Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer | recruiting | N/A | 150 | Roswell Park Cancer InstituteOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05620329 | UNC Pleural Fluid Registry | recruiting | — | 9,999 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05784922 | Health Opportunities and Promoters of Equitable Screening for Lung Cancer(HOPES) | recruiting | — | 2,000 | Massachusetts General HospitalOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06784193 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 180 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT03551951 | Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow | recruiting | — | 320 | University of Missouri-ColumbiaOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT07211529 | Intraoperative Paravertebral Block and Postoperative Complications(IPVB and POCs) | recruiting | N/A | 500 | Tongji HospitalOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT05384769 | Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer | recruiting | N/A | 108 | City of Hope Medical CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT06305715 | Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X) | recruiting | Phase 2 | 34 | Medical College of WisconsinOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT06960291 | Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada(EXCEL) | recruiting | N/A | 740 | University of CalgaryOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07207395 | A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. | recruiting | Phase 2 | 30 | The Christ HospitalOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07179692 | CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | recruiting | Phase 1 | 108 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07202611 | DC/NK Cell Therapy | recruiting | Phase 2 | 10 | National Taiwan University Clinical Trial CenterOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07181499 | Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI | recruiting | Phase 2 | 28 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198217 | Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient | recruiting | Phase 2 | 20 | Zibo Municipal HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07199959 | Study on the Mechanism of Acquired Resistance of Entrectinib | recruiting | — | 38 | Fudan UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05956587 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 121 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06623136 | A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07193641 | A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC | recruiting | Phase 2 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05037331 | Osimertinib for Advanced EGFR-positive NSCLC Patients | recruiting | — | 58 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05203328 | Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy | recruiting | N/A | 198 | The Cooper Health SystemOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06448572 | EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.(EXLIBRIS) | recruiting | Phase 1 / Phase 2 | 21 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06838208 | Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | recruiting | Phase 2 | 56 | Anhui Provincial Cancer HospitalOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT00900419 | Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers | recruiting | — | 700 | University of Colorado, DenverOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06210815 | A Study of HLX42 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 102 | Shanghai Henlius BiotechINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05541744 | The Use of Molecular Radiogenomics in Non-small Cell Lung Cancer(NSCLC) | recruiting | — | 120 | Buddhist Tzu Chi General HospitalOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07182214 | An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers. | recruiting | — | 1,340 | Pharus Taiwan, Inc.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04790682 | LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG(LIBERTYLUNG) | recruiting | N/A | 300 | Institut CurieOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06505824 | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07180823 | The LungVision Navigational Platform for Preoperative Labeling of Pulmonary Ground Glass Nodules With Fiducial Markers | recruiting | N/A | 5 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06021483 | Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection | recruiting | — | 300 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07161882 | ALG-LungCancerRegistry (SAFRO2202)(SAFRO2202) | recruiting | — | 3,750 | Société Algérienne de Formation et de Recherche en OncologieOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03958240 | Deciphering Mechanisms Underlying Cancer Immunogenicity(DECIDE) | recruiting | N/A | 1,100 | Institut Claudius RegaudOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06840782 | First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.(OliGRAIL) | recruiting | Phase 3 | 124 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 414 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06732193 | Fissios© and Postoperative Complications (FPoC Trial)(FPoC) | recruiting | N/A | 560 | Carlos Alfredo Fraile Olivero, MD, PhD.OTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05094843 | The Cardiac Stress and Electrocardiographic Changes Caused by Lung Cancer Surgery | recruiting | — | 100 | Tampere University HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05277844 | Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC(TARGET-01) | recruiting | Phase 2 | 106 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05278052 | Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC(TARGET-02) | recruiting | Phase 3 | 190 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05557487 | Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration(TRIO) | recruiting | — | 6,618 | Gee-Chen ChangOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06202222 | Interest of Intensive Postoperative Rehabilitation Following Minimally Invasive Lung Resection(IRPOL) | recruiting | N/A | 184 | University Hospital, RouenOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07166003 | Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer(NeoIP-Lung) | recruiting | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 10, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Oct 24, 2025source: clinicaltrials